# iPRRT (NCT05583708)

> Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer

No report yet. It can be ordered.

- Drugs tested: lutetium lu 177 dotatate plus pembrolizumab
- Indication: Merkel cell carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05583708
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Weill Medical College of Cornell University
- Conditions: Merkel Cell Carcinoma
- Interventions: Pembrolizumab; Lutetium Lu 177 dotatate
- Enrollment: 18
- Primary outcome: Objective Response Rate (ORR)

## Indexed commentary on iPRRT so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 4 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=iprrt-nct05583708